J. Erby Wilkinson

TL;DR: It is reported that rapamycin, an inhibitor of the mTOR pathway, extends median and maximal lifespan of both male and female mice when fed beginning at 600 days of age.

TL;DR: Evaluation of rapamycin's effects on mice is likely to help delineate the role of the mammalian target ofRapamycin complexes in the regulation of aging rate and age-dependent diseases and may help to guide a search for drugs that retard some or all of the diseases of aging.

TL;DR: It is reported that genetic loss or systemic knockdown of Malat1 using antisense oligonucleotides (ASOs) in the MMTV-PyMT- and Her2/neu-amplified tumor organoids model results in slower tumor growth accompanied by significant differentiation into cystic tumors and a reduction in metastasis.

TL;DR: New pharmacological models for exploring processes that regulate the timing of aging and late‐life diseases are provided, and in particular for testing hypotheses about sexual dimorphism in aging and health are tested.

TL;DR: The results elucidated the intricate cross-talk between p53 and miR-34 miRNAs and revealed an important tumor suppressor effect generated by this positive feedback loop.